Okamoto et al. demonstrated that the subsets of gastric cancer cells defined by a response to Src or tyrosine-protein kinase Met (MET) inhibitors were distinct, suggesting the analysis of MET amplification in the selection of patients to be treated with Src inhibitors [103,104]. This evidence concerns the gene SRC and gastric cancer.